Incyte (INCY) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs
May 1, 2018 7:00 AM EDTTotal product-related revenues of $382 million in Q1 2018, representing 30 percent growth over the same period last year; Jakafi® (ruxolitinib) revenues of $314 million in Q1 2018, representing 25 percent growth over the same period last year FDA Advisory Committee recommended approval of baricitinib 2mg for the treatment of moderately-to-severely active rheumatoid arthritis Management to highlight corporate growth and development portfolio in oncology and other indications at investor and analyst event on June 21, 2018
First-Quarter Conference Call and Webcast Scheduled Today at 8:00 a.m. ET
WILMINGTON,... More
